MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciae491

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025

Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.

White Elizabeth B, Grant Lauren, Mak Josephine, Olsho Lauren, Edwards Laura J, Naleway Allison, Burgess Jefferey L, Ellingson Katherine D, Tyner Harmony, Gaglani Manjusha, Lutrick Karen, Caban-Martinez Alberto, Newes-Adeyi Gabriella, Duque Jazmin, Yoon Sarang K, Phillips Andrew L, Thompson Mark, Britton Amadea, Flannery Brendan, Fowlkes Ashley

СтатьяПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Previous estimates of vaccine effectiveness (VE) against asymptomatic influenza virus infection based on seroconversion have varied widely and may be biased. We estimated 2022-2023 influenza VE against illness and asymptomatic infection in a prospective cohort.

METHODS

In the HEROES-RECOVER cohort, adults at increased occupational risk of influenza exposure across 7 US sites provided weekly symptom reports and nasal swabs for reverse transcription-polymerase chain reaction (RT-PCR) influenza testing. Laboratory-confirmed influenza virus infections were classified as symptomatic (≥1 symptom) or asymptomatic during the week of testing. Participants reported demographic information and vaccination through surveys; most sites verified vaccination through medical record and immunization registry review. Person-time was calculated as days from the site-specific influenza season start (September-October 2022) through date of infection, study withdrawal, or season end (May 2023). We compared influenza incidence among vaccinated versus unvaccinated participants overall, by symptom status, and by influenza A subtype, using Cox proportional hazards regression adjusted for site and occupation. We estimated VE as (1 - adjusted hazard ratio) × 100%.

RESULTS

In total, 269 of 3785 (7.1%) participants had laboratory-confirmed influenza, including 263 (98%) influenza A virus infections and 201 (75%) symptomatic illnesses. Incidence of laboratory-confirmed influenza illness among vaccinated versus unvaccinated participants was 23.7 and 33.2 episodes per 100 000 person-days, respectively (VE: 38%; 95% CI: 15%-55%). Incidence of asymptomatic influenza virus infection was 8.0 versus 11.6 per 100 000 (VE: 13%; 95% CI: -47%, 49%).

CONCLUSIONS

Vaccination reduced incidence of symptomatic but not asymptomatic influenza virus infection, suggesting that influenza vaccination attenuates progression from infection to illness.

Для цитирования: White Elizabeth B, Grant Lauren, Mak Josephine, Olsho Lauren, Edwards Laura J, Naleway Allison, Burgess Jefferey L, Ellingson Katherine D, Tyner Harmony, Gaglani Manjusha, Lutrick Karen, Caban-Martinez Alberto, Newes-Adeyi Gabriella, Duque Jazmin, Yoon Sarang K, Phillips Andrew L, Thompson Mark, Britton Amadea, Flannery Brendan, Fowlkes Ashley. Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025. DOI: 10.1093/cid/ciae491.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.